ContraFect Corporation ContraFect Corporation Nasdaq: CFRX

Navigate ContraFect Corporation

  • Home
  • About Us
    • Overview
    • Management Team
    • Board of Directors
  • Technology
    • Overview
    • Lysins
    • Amurins
    • Publications / Posters
    • Video Library
  • Pipeline
    • Overview
    • Exebacase
    • CF-370
    • Gram-negative Lysins
    • Amurins
  • Investors & Media
    • Overview
    • News / Events
    • Presentations
    • Company Information
    • Financial Information
    • Analyst Coverage
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Careers
  • Contact Us

Press Releases

Investors & Media

  • Home
  • Investors & Media
  • News / Events
  • Press Releases
Investors & Media

Investors & Media

  • Overview
  • News / Events
    • Press Releases
    • Media Coverage
    • Events
    • Email Alerts
  • Presentations
  • Company Information
  • Financial Information
  • Analyst Coverage
  • Stock Data
  • SEC Filings
  • Corporate Governance
  • Email Alerts
  • Tear Sheet
  • Contacts
  • RSS News Feed
  • All News
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010

ContraFect Announces Presentation of New Data from its Amurin Peptide Program at the ASM/ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance

August 28, 2019

ContraFect Reports Second Quarter 2019 Financial Results and Provides Business Update

August 9, 2019

ContraFect Announces ASM Microbe 2019 Outstanding Abstract Award and Presentation of New Data

June 17, 2019

ContraFect Awarded $7.2 Million USAMRDC Grant to Support the Advancement of Lysin Candidate CF-296

June 6, 2019

ContraFect Announces Presentation at the International Society of Cardiovascular Infectious Diseases Symposium

June 3, 2019

ContraFect Announces Publication of Paper on Recent Exebacase Data in Antimicrobial Agents and Chemotherapy Journal

May 31, 2019

ContraFect Reports First Quarter 2019 Financial Results and Provides Business Update

May 10, 2019

ContraFect to Host R&D Symposium on Direct Lytic Agents (Lysins and Amurins) with Clinical Thought Leaders on Infectious Disease

May 8, 2019

ContraFect Presents Additional Positive Data from the Phase 2 Trial of Exebacase at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

April 16, 2019

ContraFect Announces Publication of Exebacase Data in Antimicrobial Agents and Chemotherapy Journal

April 8, 2019

RSS
  • « Previous
  • 1...
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • ...23
  • Next »
© 2023 ContraFect Corporation. All Rights Reserved.
Copyright Privacy Policy Expanded Access Policy Disclaimer Site Map
LinkedIn Twitter